A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Clinical trial NCT05458297 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05458297
Sponsor: Merck Sharp & Dohme LLC
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia Mantle Cell Lymphoma Follicular Lymphoma Richter Transformation Lymphoma

Start date: 2022-07-21
Primary completion: 2029-05-17
Enrollment: 189

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.